The readout for Firmonertinib has moved to mid-2026, which may reflect slower event accumulation and potentially longer ...

Last participant has been randomized and dosed in the Phase 3 APOLLO study of bitopertin in erythropoietic protoporphyria (EPP)The study size was expanded to 183 participants due to patient and ...

Starting in the spring of 2026, the Factory at Franklin will open a new museum so that visitors can learn more about the area ...

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today reported its business update and consolidated financial results for the year ending December 31, 2025. The ...

By Valentina Za MILAN, March 24 (Reuters) - Banca Monte dei Paschi di Siena said its board had chosen Fabrizio Palermo as its ...

Ord Minnett says while risks persist, the local healthcare sector is a defensive haven in these troubled geopolitical times. ...

ARMS three-phase inverter platform built around the Gen-7 EPC2366 eGaN® power transistor, showcased at EPC’s booth ...

Despite its enormous global burden, osteoarthritis has no licensed disease-modifying treatments, and available analgesics have moderate efficacy and substantial side-effects.1 The success of ...

SAN FRANCISCO and SUZHOU, China, March 23, 2026 /PRNewswire/ -- Innovent Biologics, Inc. (\"Innovent\", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and ...

Building on the success of GLOW1 and with all patients on a 6-month dosing interval, Zenkuda (tarcocimab tedromer) demonstrated superiority to sham with 62.5% of Zenkuda-treated patients achieving ...

The proposal is aimed at providing underprivileged children opportunities on par with those studying in elite private ...

Innovent Biologics, Inc. ('Innovent', HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and ...